CSPC Megalith Biopharmaceutical Co.,Ltd.

Quick facts

Phase 2 pipeline

• A zoster mRNA vaccine SYS6017 · Immunology / Infectious Disease
  SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster.
• Investigator's choice of SOC

Phase 1 pipeline

• monotherapy chemotherapy
• SYH2051 tablets
• SYS6005
• SYS6010 jnjection
• SYS6023
• SYS6045

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CSPC Megalith Biopharmaceutical Co.,Ltd. portfolio CI brief
• CSPC Megalith Biopharmaceutical Co.,Ltd. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies